Noom GLP-1 review: Noom med and the microdose plan

Noom’s GLP-1 program, Noom Med, prescribes three kinds of medication: compounded semaglutide or tirzepatide, including a lower-dose “microdose” plan at $79 for the first order and $179 a month after that; generic liraglutide; and brand-name GLP-1s on a $129 monthly membership. It is a real program with licensed clinicians, LegitScript certification and an A+ BBB rating, but microdosing is not an FDA-approved way to take any GLP-1, and in May 2026 the advertising industry’s self-regulatory body asked Noom to change a microdose claim that Eli Lilly had challenged. Prices here are Noom’s own, as of October 2026.

What Noom Med is

Noom, Inc. started as a weight-loss app with coaching; Noom Med adds prescriptions. You take an online intake survey, a licensed clinician evaluates it and prescribes online if appropriate, and you get unlimited access to your clinician alongside Noom’s coaching. Noom’s terms say Noom itself isn’t a healthcare provider: care comes from outside clinical partners, and pharmacy partners fill prescriptions. The terms don’t name those partners.

Outside employer and health plan programs, Noom Med is cash pay, and its terms say Noom isn’t a participating provider with Medicare or Medicaid. Noom says the program is FSA and HSA eligible, and it isn’t available in all 50 states. Its site displays a LegitScript Certified badge that links to LegitScript’s lookup for noom.com; we checked it on Oct 27, 2026. LegitScript certification reviews licensing and pharmacy practices, not the quality of care. We searched the FDA’s warning letter pages for Noom on the same day and found no warning letter.

What Noom prescribes, and what it costs

Noom says its current pricing applies to new accounts from July 27, 2026. On the brand-name path, the $129 membership adds $1,548 a year on top of the drug.

The compounded options need plain facts. Noom’s compounded semaglutide and tirzepatide are not Wegovy, Ozempic, Zepbound or Mounjaro, and not generics of them. A compounding pharmacy prepares them, and they aren’t FDA-approved. Noom’s own footnote says its compounded semaglutide “has not been reviewed by the FDA for safety, efficacy, or quality.” See our compounded GLP-1 page for how these drugs are regulated, and our liraglutide page for the generic.

Ozempic and Mounjaro are approved for type 2 diabetes, so using them for weight loss alone is off-label. The Wegovy and Zepbound labels open with a boxed warning about the risk of thyroid C-cell tumors, and say not to use them with a personal or family history of medullary thyroid carcinoma or MEN 2. Compounded versions have no FDA label of their own, so give your clinician your full history and ask how that warning applies to you.

Noom microdose: what it is, and why it’s off-label

Noom describes its microdose plan as “lower doses of medication designed by our Chief Medical Officer,” with the same coaching and clinical care as its other plans. It doesn’t publish the doses.

Microdosing isn’t an approved way to take any GLP-1. When the FDA approves a drug, it approves the doses on its label, and no GLP-1 label includes a microdose schedule. A dose below the label’s schedule for Wegovy or Zepbound is off-label use, and compounded semaglutide and tirzepatide have no FDA label at all. The FDA says a doctor may prescribe off-label when they judge it medically appropriate, but for that use the agency “has not determined that the drug is safe and effective.” Our guide to GLP-1 microdosing covers the lowest label doses and what the research shows.

Noom’s page also cites weight-loss figures for the plan. Its footnote says they come from Noom users’ self-reported data, not from a clinical trial.

The claim Eli Lilly challenged

Eli Lilly, which makes Zepbound and Mounjaro, challenged Noom’s microdose advertising at the National Advertising Division (NAD), the advertising industry’s self-regulatory body, run by BBB National Programs. The challenged ad read: “Noom GLP-1Rx Program A Smaller Dose. A Smarter Start. Microdose GLP-1Rx Starts at $119.”

In a decision announced on May 26, 2026, the NAD found that one message the ad conveyed was that Noom’s product is “smarter” because of its “smaller” dose, and that Noom hadn’t adequately supported the message that its lower-dose approach gives a measurable health benefit. It recommended that Noom discontinue the claim or change its advertising so it doesn’t convey that message. Noom also told the NAD it was permanently dropping the other challenged claims, about dosing, efficacy, side effects and other health benefits, so the NAD didn’t rule on those. Noom said it disagreed with the conclusion but would comply. The NAD added that Noom can still promote its program and its behavior-change tools as a smarter start, as long as the ad doesn’t tie that message to unsupported dose-related benefits.

The NAD isn’t a regulator and this wasn’t a lawsuit. What it tells you is that Noom didn’t back the idea that its smaller dose is better for you with evidence the NAD accepted.

How the microdose price compares

At $179 a month after the first order, the microdose plan costs more than the market median for a standard dose. Among the 26 programs we rank, the lowest ongoing all-in price for compounded semaglutide runs from $65 to $299 a month, with a median of $173.50, and for compounded tirzepatide from $85.58 to $378.08, with a median of $240. Noom’s standard-dose plan, at $249 a month, sits well above the semaglutide median. Keep two things in mind: the microdose plan is a lower dose, and after the first order it runs on a 12-week subscription. Among programs we list, Measured’s compounded semaglutide microdose plan was $99 a month ($79 on a current sale) as of November 2026. Compare GLP-1 microdosing providers and the cheapest GLP-1 programs.

Noom reviews: what the ratings say

Scroll sideways to see the full table

Both were read on Oct 27, 2026. The Trustpilot profile covers the Noom app and coaching as well as Noom Med, and only 2,404 of its reviews are from the last 12 months, so the 4.5 isn’t a score for the GLP-1 program alone. In the 1-star reviews shown that day, the themes were wrong or delayed medication shipments with slow replacements, support that was hard to reach or answered by a chatbot, and billing and account problems.

Cancelling Noom Med, and refunds

From Noom’s terms, read on Oct 27, 2026:

• Cancel from your account page before 11:59 p.m. Eastern time on the day before your next billing date, or you’ll be charged for the next period.
• Noom doesn’t refund partly used billing periods, and its terms say fees are generally non-refundable unless the law requires a refund or a Noom promotion you qualify for offers one.
• California residents can cancel within 3 business days of signing up and get a refund.
• The microdose plan moves to a 12-week subscription after the first order, so check your renewal date before it starts.

The bottom line

Noom Med is a legitimate program that suits people who want coaching and an app as much as a prescription, with compounded, generic and brand-name options in one place. Be clear about what the microdose plan is: a compounded drug at doses no FDA label covers, sold on a 12-week subscription, and promoted at first with a “smarter start” claim that Noom agreed to change after Lilly’s challenge. If you want an FDA-approved drug, the brand-name path costs $129 a month on top of the medication.

Other options

If you want to compare Noom with the rest of the market:

• GLP-1 microdosing providers
• Compounded semaglutide providers and compounded tirzepatide providers, ranked by our published score
• The cheapest GLP-1 programs, ordered by price
• Brand-name GLP-1 programs
• Every program we cover in weight loss